BG
MDCO

Bellevue Group’s Medicines Co MDCO Stock Holding History

Bellevue Group’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-28,900
Closed -$1.45M – 231
2019
Q3 		$1.45M Sell
28,900
-14,600
-34% -$582K 0.03% 130
2019
Q2 		$1.59M Buy
43,500
+14,500
+50% +$473K 0.03% 135
2019
Q1 		$811K Buy
+29,000
New +$683K 0.04% 129
2018
Q3 		– Sell
-17,050
Closed -$626K – 146
2018
Q2 		$626K Sell
17,050
-550
-3% -$17.9K 0.05% 131
2018
Q1 		$580K Sell
17,600
-250
-1% -$7.81K 0.06% 116
2017
Q4 		$488K Sell
17,850
-1,650
-8% -$50.8K 0.05% 126
2017
Q3 		$722K Hold
19,500
– – 0.08% 114
2017
Q2 		$741K Sell
19,500
-2,000
-9% -$89.1K 0.09% 116
2017
Q1 		$1.05M Buy
+21,500
New +$981K 0.14% 102

Other funds holding MDCO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Bellevue Group's MDCO Position: Q4 2019 in Review

Bellevue Group sold out of Medicines Co (MDCO) in Q4 2019, closing a stake of 28,900 shares — an estimated $1.45M sold.

Bellevue Group first reported a position in MDCO in Q1 2017 and held it in 9 quarters. The position peaked at $1.59M in Q2 2019. 284 funds tracked by Wall St. Rank hold MDCO as of Q4 2019.

  • Bellevue Group reported no remaining Medicines Co position as of Q4 2019 after selling out during the quarter.
  • Bellevue Group sold 28,900 Medicines Co shares in Q4 2019, an estimated $1.45M.
  • Bellevue Group first reported a position in Medicines Co in Q1 2017 and held it in 9 quarters.
  • Bellevue Group's Medicines Co position peaked at $1.59M in Q2 2019.
  • 284 funds tracked by Wall St. Rank held Medicines Co as of Q4 2019.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.